Biography and Research Information
OverviewAI-generated summary
Divaya Bhutani's research focuses on the treatment of hematologic malignancies, particularly multiple myeloma and immunoglobulin light-chain amyloidosis (AL amyloidosis). Her work investigates the efficacy and safety of novel therapeutic agents and treatment regimens in these conditions.
Recent publications by Bhutani examine the use of daratumumab-based treatments and venetoclax for AL amyloidosis, as well as the role of monoclonal antibody CAEL-101. She has also published on the outcomes of teclistamab in relapsed refractory multiple myeloma and systemic immunoglobulin light chain amyloidosis, and the evolving spectrum of infections associated with bispecific antibody therapy in multiple myeloma. Further research includes studies on pembrolizumab combined with dinaciclib for hematologic malignancies and front-line daratumumab-based therapy for AL amyloidosis.
Bhutani's scholarship metrics include an h-index of 25, 183 total publications, and 2,670 total citations. She is recognized as a highly cited researcher. Her key collaborators at the University of Arkansas for Medical Sciences include Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, and Samer Al Hadidi, with whom she has co-authored multiple publications.
Metrics
- h-index: 25
- Publications: 183
- Citations: 2,670
Selected Publications
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
Collaboration Network
Top Collaborators
- Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Showing 5 of 38 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- First report of outcomes in patients with stage I<scp>IIb AL</scp> amyloidosis treated with <scp>Dara–VCD</scp> front‐line therapy
- How do we manage t(11;14) plasma cell disorders with venetoclax?
Showing 5 of 33 shared publications
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
- First report of outcomes in patients with stage I<scp>IIb AL</scp> amyloidosis treated with <scp>Dara–VCD</scp> front‐line therapy
- Reduced early mortality with <scp>Daratumumab‐based</scp> frontline therapy in <scp>AL</scp> amyloidosis: A retrospective cohort study
- Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects
- Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis
Showing 5 of 16 shared publications
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
- First report of outcomes in patients with stage I<scp>IIb AL</scp> amyloidosis treated with <scp>Dara–VCD</scp> front‐line therapy
- Reduced early mortality with <scp>Daratumumab‐based</scp> frontline therapy in <scp>AL</scp> amyloidosis: A retrospective cohort study
- Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy
- Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis
Showing 5 of 11 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 10 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 10 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 10 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 9 shared publications
- First report of outcomes in patients with stage I<scp>IIb AL</scp> amyloidosis treated with <scp>Dara–VCD</scp> front‐line therapy
- Reduced early mortality with <scp>Daratumumab‐based</scp> frontline therapy in <scp>AL</scp> amyloidosis: A retrospective cohort study
- Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis
- High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy
- EFFECT OF DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE ON CARDIAC FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED AL AMYLOIDOSIS WITH CARDIAC INVOLVEMENT: RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
Showing 5 of 8 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Showing 5 of 8 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Showing 5 of 8 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Showing 5 of 8 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Showing 5 of 8 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Showing 5 of 8 shared publications
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy
- Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis
- Updated OS of patients with AL amyloidosis after CAEL-101.
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics